OrganiGram Holdings Inc. (OGI.TO)
CAD 2.1
(-7.89%)
CAD 2.1
(-7.89%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -207.61 Million CAD | -66.78% |
| 2022 | 12.32 Million CAD | 64.57% |
| 2021 | -95.59 Million CAD | 47.06% |
| 2020 | -121.47 Million CAD | -690.1% |
| 2019 | 15 Million CAD | -65.6% |
| 2018 | 39.94 Million CAD | 515.39% |
| 2017 | -8.99 Million CAD | -573.41% |
| 2016 | 2.03 Million CAD | 372.96% |
| 2015 | -746.65 Thousand CAD | -797.03% |
| 2014 | 106.76 Thousand CAD | 128.45% |
| 2013 | -375.24 Thousand CAD | -167.72% |
| 2012 | -140.16 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -21.24 Million CAD | -84.98% |
| 2024 Q3 | -15.85 Million CAD | 125.34% |
| 2024 Q1 | -13.02 Million CAD | 62.09% |
| 2023 Q2 | -4.2 Million CAD | -140.21% |
| 2023 Q3 | -21.65 Million CAD | -415.18% |
| 2023 Q4 | -33.93 Million CAD | -56.74% |
| 2023 Q1 | 10.45 Million CAD | 13853.95% |
| 2023 FY | - CAD | -480.12% |
| 2022 Q4 | -76 Thousand CAD | 98.72% |
| 2022 Q3 | -5.91 Million CAD | -317.87% |
| 2022 Q2 | -1.41 Million CAD | 81.85% |
| 2022 FY | - CAD | 64.57% |
| 2022 Q1 | -7.8 Million CAD | -277.72% |
| 2021 Q2 | -21.7 Million CAD | -1.62% |
| 2021 Q3 | -4.25 Million CAD | 80.37% |
| 2021 Q4 | 4.38 Million CAD | 203.05% |
| 2021 Q1 | -21.35 Million CAD | 46.06% |
| 2021 FY | - CAD | 47.06% |
| 2020 Q3 | -53.77 Million CAD | -1075380.0% |
| 2020 Q4 | -39.58 Million CAD | 26.38% |
| 2020 FY | - CAD | -690.1% |
| 2020 Q1 | 3.25 Million CAD | 113.45% |
| 2020 Q2 | -5000.00 CAD | -100.15% |
| 2019 Q4 | -24.21 Million CAD | -154.76% |
| 2019 Q1 | 47.93 Million CAD | 62.49% |
| 2019 Q3 | -9.5 Million CAD | -1909.51% |
| 2019 FY | - CAD | -65.6% |
| 2019 Q2 | -473 Thousand CAD | -100.99% |
| 2018 Q3 | 8.56 Million CAD | 201.26% |
| 2018 FY | - CAD | 515.39% |
| 2018 Q4 | 29.49 Million CAD | 244.31% |
| 2018 Q2 | 2.84 Million CAD | 394.56% |
| 2018 Q1 | -965.45 Thousand CAD | 39.38% |
| 2017 Q1 | -416.19 Thousand CAD | -143.87% |
| 2017 Q2 | -5.52 Million CAD | -1227.45% |
| 2017 Q3 | -2.08 Million CAD | 62.31% |
| 2017 Q4 | -1.59 Million CAD | 23.53% |
| 2017 FY | - CAD | -573.41% |
| 2016 Q3 | 695.71 Thousand CAD | 87.96% |
| 2016 Q4 | 948.62 Thousand CAD | 36.35% |
| 2016 FY | - CAD | 372.96% |
| 2016 Q1 | 16.75 Thousand CAD | -92.32% |
| 2016 Q2 | 370.13 Thousand CAD | 2109.79% |
| 2015 Q2 | -520.88 Thousand CAD | 30.47% |
| 2015 Q1 | -749.2 Thousand CAD | -298.75% |
| 2015 Q4 | 218.12 Thousand CAD | -28.56% |
| 2015 FY | - CAD | -797.03% |
| 2015 Q3 | 305.31 Thousand CAD | 158.61% |
| 2014 Q4 | -187.88 Thousand CAD | -646.03% |
| 2014 Q2 | -15.69 Thousand CAD | -109.79% |
| 2014 Q1 | 160.31 Thousand CAD | 1365.0% |
| 2014 FY | - CAD | 128.45% |
| 2014 Q3 | -25.18 Thousand CAD | -60.49% |
| 2013 Q2 | -58.7 Thousand CAD | 76.78% |
| 2013 Q1 | -252.8 Thousand CAD | -315.97% |
| 2013 Q3 | -2962.00 CAD | 94.95% |
| 2013 Q4 | -12.67 Thousand CAD | -327.85% |
| 2013 FY | - CAD | -167.72% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q3 | -43.44 Thousand CAD | 46.39% |
| 2012 Q2 | -81.03 Thousand CAD | -1168.18% |
| 2012 Q1 | -6390.00 CAD | 31.26% |
| 2012 Q4 | -60.77 Thousand CAD | -39.9% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q4 | -9296.00 CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aurora Cannabis Inc. | 20.47 Million CAD | 1114.062% |
| Avicanna Inc. | -7.35 Million CAD | -2722.653% |
| Avant Brands Inc. | 4.83 Million CAD | 4393.2% |
| Cardiol Therapeutics Inc. | -27.87 Million CAD | -644.69% |
| Crescita Therapeutics Inc. | 45 Thousand CAD | 461475.902% |
| Knight Therapeutics Inc. | 40.89 Million CAD | 607.664% |
| MediPharm Labs Corp. | -10.47 Million CAD | -1881.477% |
| Canopy Growth Corporation | -312.82 Million CAD | 33.631% |
| Willow Biosciences Inc. | -11.06 Million CAD | -1777.038% |
| Auxly Cannabis Group Inc. | -10.82 Million CAD | -1817.96% |